Scarica l'app Stockscreener
12.25
3.14%
-0.3974
Dopo l'orario di chiusura:
12.12
-0.1311
-1.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FIXX Giù?
Forum
Previsione
Homology Medicines Inc Borsa (FIXX) Ultime notizie
Q32 Bio (FIXX) CSO logs automatic sale of 2,798 shares - Stock Titan
Q32 Bio (NASDAQ: FIXX) CFO’s 3,972-share tax sale detailed - stocktitan.net
Q32 Bio (FIXX) CEO’s automatic tax sale leaves 343,259 shares - Stock Titan
Mucopolysaccharidosis Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
Leverage Shares 2X Long FIX Daily ETF ETF Price, Holdings, & News (BATS:FIXX) $FIXX - MarketBeat
Antineutrophil Cytoplasmic Antibody (ANCA) Associated - openPR.com
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Mucolipidosis II Market - openPR.com
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Vitiligo Therapeutics Market Projected to Reach USD 2.28 Billion by 2032 - Yahoo Finance
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Canada
Form 424B5 Q32 Bio Inc For: 13 July By Investing.com - Investing.com Canada
Nucleic Acid Based Gene Therapy Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary - Weekly Voice
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
QTTBQ32 Bio Inc Stock Price and Quote - Finviz
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Sahm
Obesity Treatment Development: Challenges and Future Focus - Technology Networks
Mucolipidosis II Market Analysis: Major Segments, Strategic Developments, and Leading Companies - openPR.com
ATLAS VENTURE ASSOCIATES X L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Leading Companies Fueling Innovation and Growth in the Mucopolysaccharidosis Treatment Market - openPR.com
DEERFIELD PARTNERS L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Krabbe Disease Treatment Market Overview, Emerging Trends, and Key Player Analysis - openPR.com
Analysis of Key Market Segments Influencing the CRISPR Gene Editing Market - openPR.com
Deerfield Mgmt HIF L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Growth Patterns, Segment Analysis, and Competitive Approaches - openPR.com
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Analysis of Market Segments and Major Growth Areas in the Nucleic Acid Based Gene Therapy Market - openPR.com
Biotech Expansion Accelerating Viral Vector Manufacturing Market Insights 2026–2035 - Weekly Voice
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - Sahm
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire
Editas Medicine nominates lead in vivo development candidate - BioWorld News
AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire
OXB completes acquisition of remaining stake in US subsidiary - GlobeNewswire
Mucopolysaccharodisis Treatment Market Size & Share, 2033 - Market Data Forecast
Qatar’s $320bn wealth fund seeks to catch up on tech - businessreport.co.za
Stoke Therapeutics Announces CEO Transition - Business Wire
Q32 Bio Inc. (QTTB) reports earnings - qz.com
Versatope Adds New Board Members - citybiz
QTTB stock touches 52-week low at $2.59 amid market challenges - Investing.com
Homology Medicines (NASDAQ: FIXX)Share Price - intelligentinvestor.com.au
100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033 - GlobeNewswire
Oxford BioMedica H1 Loss Narrows, Revenues Climb; Confirms FY24, Medium-term Outlook - RTTNews
Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina - Frontiers
Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz
QTTB reaches 52-week high, hitting $32.99 - Investing.com
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments - BioPharma Dive
Phenylketonuria Pipeline and Clinical Trials Assessment 2024: - openPR.com
Timothy P Kelly Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform - Business Wire
Homology Medicines Defeats Investor Suit Over Clinical Trial (1) - Bloomberg Law News
Q32 Bio Closes Merger with Homology Medicines - citybiz
Homology Medicines approves 1-for-18 reverse stock split By Investing.com - Investing.com India
Homology Medicines Declares Distribution to Common Stockholders | FIXX Stock News - Stock Titan
EDGAR Filing Documents for 0001193125-23-278325 - SEC.gov
Oxford Biomedica enters US through $180m Homology JV - BioProcess International
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases - PR Newswire
Analytical characterization of full, intermediate, and empty AAV capsidsGene Therapy - Nature
Neurogene Appoints Julie Jordan, M.D., as Chief Medical Officer - citybiz
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - Stock Titan
The definitive Boston biotech layoff tracker for 2023 - The Business Journals
Latham & Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio - Latham & Watkins LLP
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):